Frontline BTKi Selection

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.

EP: 1.Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

EP: 2.Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

Now Viewing

EP: 3.Frontline BTKi Selection

EP: 4.Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

EP: 5.Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

EP: 6.Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

EP: 7.EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

EP: 8.Navigating Treatment Approaches for R/R CLL

EP: 9.How Experts View MAIC Data That was Presented at EHA 2024

EP: 10.BTKi Intolerance in Real-world Practice & Management Strategy

EP: 11.Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

EP: 12.Approach to Hypertension Management With BTKi Treatment

EP: 13.Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

EP: 14.Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

EP: 15.Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

EP: 16.TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

EP: 17.EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

EP: 18.Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

EP: 19.Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

EP: 20.Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

EP: 21.Clinical Pearls and Impacts to Practice from EHA 2024

Dr Lamanna: When considering continuous BTKi therapy in the front-line setting, how do you select among available treatment options?
1. How do you select patients for acala vs zanu?
2. In which patients would you consider the addition of obinutuzumab?
Dr Danilov: How important is long-term efficacy and safety data when making informed treatment decisions and how may these data shape your overall treatment approach?
Dr Coombs asks about Frontline use??
- ELEVATE-TN – 6-yr follow up (Sharman, et al. ASH 2023. Abstract 636)
- SEQUOIA – Extended Follow-up (Munir, et al. Hemasphere 2023)